+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

It is widely recognized that cellular and gene therapies (also referred to as advanced cellular therapies) hold the potential to revolutionize health care for a variety of diseases. However, the limitations of current technologies, the complexity of manufacturing, safety, efficacy and reimbursement models and understanding regulatory requirements for cell-based and cell-derived products as therapies have led to only a few players making it to the commercial stages. The cell and gene therapy industry is yet to address certain gaps relating to these limitations that will facilitate clinical and commercial success of these therapies.

Key players all over the globe are also looking to tackle some crucial needs such as scalable manufacturing (upstream and downstream), robustness and efficiencies to make these advanced cellular therapies cost effective and safe.

Taking into consideration the above issues, the Bioprocessing of Advanced Cellular Therapies Congress took place on 2-3 June 2016 at the London Heathrow Marriott Hotel - UK and presented some of the recent developments, approaches and novel technologies for bioprocessing cellular therapies. The focus was on the engineering challenges faced in this field with respect to bioprocessing from early process development to manufacturing scales.
It aimed to support the delegates in successful translation of unique bioprocesses to robust, scaled manufacturing production for successful clinical translation. The two-day congress concluded with a summary into key aspects around regulatory requirements, business development and reimbursement insights.
Key sessions:
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives

Key Speakers at the Conference:
Chris Mason, Professor Of Regenerative Medicine, University College Of London, UK
Otto-Wilhelm Merten, Head Of The Applied Vectorology And Innovation, Généthon, France
Bo Kara, Head Process Development, Advanced Therapy DeliveryGSK, UK
Anne Plant, Program Director For Biosciences, NIST, USA
Paula Marques Alves, Chief Executive Officer, IBET, Portugal
Steve OhDirector Stem Cell Bioprocessing, Bioprocessing Technology Institute, Singapore
John GrayVP, R&DAudentes, USA

Post Show Report  2016:

Click here to view post show report of Bioprocessing of Advanced Cellular Therapies Congress 2016

conference Registration Form



Academic Delegate£495
Industry Delegate £795
Solution Provider Delegate£995


 Upstream process development for gene therapies

  • This session targets main challenges and bottlenecks in upstream processing of gene therapies. Right from discussing robust strategies for cell line selection to developing scalable and validatable, established and novel, manufacturing processes for these products.

• Upstream process development for cell-based therapies

  • Following the drive to better understand and control processes by implementing initiatives such as Quality by Design (QbD) and process analytical technology (PAT), this session will address these two topics in relation to the process development of upstream platforms for cell-based therapies.

 Downstream processing considerations

  • This session intends to cover established and novel approaches to address current challenges related to the downstream processing of cell and gene therapies. Presenting optimisation, development and innovation of purification technologies to ultimately address cost-effectiveness of these therapies by increasing product yield, quality and potency. Moreover, it will consider the role of scale - down models in developing large - scale manufacturing processes that are scalable, robust and cost-effective.

• Moving away from clean rooms to modular closed manufacturing

  • The race to be the first and the best is more intense than ever. The fierce competition and challenging economic models for these therapies have created a demand for multi-purpose highly flexible facilities. As a result of these needs, industry is looking to move towards closed, modular manufacturing models. Our panel of experts will discuss what this entails for the industry with respect to relevant practical considerations such as (but not limited to) automation by implementation of automated PAT strategies and their capacity to eliminate gaps in real-time process monitoring.

• Analytics - tackling measurement assurance for advanced cellular therapeutics

  • Following the previous discussion, this session hopes to provide further insight into analytics. Understanding and controlling measurements and sources of variability will enable us to develop an adequate QC strategy.

• Insights into business development and reimbursement

  • A very important session that will facilitate key discussions on how to tackle reimbursement strategies and how to build successful business models around complex companies for long term survival and profitability.

• Regulatory perspectives

  • This session will highlight discussions on regulatory perspectives and considerations. It aims to provide the attendees with viewpoints and perspectives from experts from various regulatory bodies from around the world.

Who Should Attend ?

Who attended?

Engineers, scientists, academics and professionals working in
• Cell Culture
• Cell Therapy
• Upstream Processing
• Biotechnology
• Stem Cell Culture
• Process Development Engineering
• Bioprocessing
• Downstream Processing
• Quality Control
• Bioengineering
• Scale-up/out
• Data management for cell-based products
Benefits of attending

• A chance to interact and network with key players in the field
• Great speaker and chair line-up will certainly ensure intellectually stimulating conversations

Advisory Panel

Fernanda Masri


Fernanda Masri

Process Development Engineer, 
Centre for Commercialization of Regenerative Medicine (CCRM)


Otto-Wilhelm Merten


Otto-Wilhelm Merten

Head of the Applied Vectorology and Innovation, Genethon, France


Ana Sofia Coroadinha


Ana Sofia Coroadinha

Head of Cell Line Development & Molecular Biotechnology,
IBET/ITQB-UNL, Animal Cell Technology Unit, Portugal


Bo Kara


Bo Kara

Head of Process Development,
Advanced Cellular Therapy Delivery, GSK - UK

Anita Joshi


Anita Joshi

Biotechnology Consultant, Healthcare | FnB,
Markets and Markets



  • Otto-Wilhelm Merten

    Head of the Applied Vectorology and Innovation,
    Généthon, France
  • Bo Kara

    Head Process Development, Advanced Therapy Delivery, GSK, UK
  • Anne Plant

    Program Director
    Biosciences NIST, USA
  • Paula Marques Alves

    Chief Executive Officer
    IBET, Portugal
  • Steve Oh

    Director, Stem Cell Bioprocessing, BIP Programme Director & Senior Principal Scientist
    Stem Cell Group Bioprocessing Technology Institute, Singapore
  • John Gray

    VP, R&D Audentes
  • Michael Kallos

    Professor & Director Biomedical Engineering Graduate Program University of Calgary, Canada
  • Dr. Sven Kili

    VP and Development Head, Gene Therapy division GSK, UK
  • Dr Robert J Thomas

    Reader in Manufacturing for Cell Based Therapies; EPSRC Early Career Fellow Centre for Biological Engineering (CBE), Wolfson School of Mechanical and Manufacturing Engineering Loughborough University, UK
  • Jurjen Velthuis

    Vice President CMC Kiadis Pharma, Netherlands
  • Peter Jones

    Head of Manufacturing Development Oxford BioMedica
  • Mark McCall

    Enterprise Fellow, Centre for Biological Engineering Loughborough University, UK
  • Margarida Menezes-Ferreira

    National Scientific Advice Coordinator, Senior Assessor/Medicines Evaluation Department INFARMED, Lisbon, Portugal
  • Olive J. Sturtevant

    Administrative Director of the Cell Manipulation Core Facility Dana Farber Cancer Institute, Boston-Massachusetts
  • Dr Marc-Olivier Baradez

    Lead Scientist Analytical Development CT Catapult
  • Dr Damian Marshall

    Head of Analytical Development CT catapult
  • Dr. Ivan Wall

    Senior Lecturer Department of Biochemical Engineering, University College London
  • Nina Kotsopoulou

    Head, Process Development Autolus Ltd, London, UK
  • Dr. Qasim Rafiq

    Assistant Professor, Bioprocess engineering Aston Medical Research Institute, Aston University, UK


Gold Sponsors


Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Our 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer.


BioSpherix manufactures the Xvivo System, the world’s first and only barrier isolator optimized for cells. It utilizes a total quality approach for culturing and processing cell and gene therapies. The Xvivo System is an economical and practical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Get better contamination control, better process control, better quality control, better pocketbook control. Stop by the BioSpherix booth!




ChemoMetec develops and manufactures high quality automated cell counters which can count aggregated cells, cells growing on microcarriers, Adipose Derived Stem Cells and advanced cell analysers - helping to streamline research and production processes for maximum efficiency. Our technology is widely deployed in fields such as cancer and stem cell research plus the production and quality control of a number of diverse products such as biopharmaceuticals, beer, animal semen and milk. Our products are well regarded for their high quality, high precision, and repeatability plus the “easy to use” advanced cell analysis functions. We strongly value our customers and our policy is “no hidden costs” – Therefore we have no extra service agreements, high levels of support and always free software updates.

Telstar UK

Telstar UK based in Dewsbury, design and manufacture containment and aseptic barrier Isolators for the pharmaceutical, healthcare, cell therapy, chemical and biotech markets. Telstar UK supply high quality
customised and standard solutions for each specific application.

Turnkey equipment packages incorporate full implementation of cGMP/GAMP documentation including IQ/OQ packages, FDS/quality plan submittals and all industry standard code considerations from our global manufacturing plants ensuring compliance, control and validation.

 LINC Medical

LINC Medical is an established important supplier of medical equipment and devices to UK healthcare providers and operates nationwide. The company’s mission is to provide excellent customer support and offer cost effective products that enhance the patients' and medical professionals' quality of life and working environment.


Irvine ScientificIrvine Scientific is a worldwide leader in the design and production of cell culture products for cell therapy, immunology, biopharmaceutical, cytogenetic, and ART applications. Our extensive experience with rational media design, cGMP manufacturing and compliance with ISO and FDA regulations uniquely positions us to support cell therapy applications from basic research through scale-up, and to the later stages of clinical development.


MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte focuses on applying its capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of diseases. MaxCyte's customers and partners utilize its technologies to develop and commercialize cell-based therapies in regenerative medicine and cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. 


CellGenix is a premium supplier of high-quality GMP reagents and tools for cell therapy and regenerative medicine applications. We offer a comprehensive product portfolio in combination with expert regulatory and technical support to ensure a seamless transition from research to commercialization. Our products combine a maximum of quality and safety due to state-of-the-art production, stringent in-house quality control and comprehensive documentation.

EppendorfEppendorf - We Know Bioprocessing
As a global leader for liquid-, cell- and sample- handling products, Eppendorf entered the bioprocess market in 2007 through the acquisition of New Brunswick™ Scientific, a global bioprocess technology leader. In 2012, Eppendorf further expanded its bioprocess expertise and product offerings by acquiring DASGIP®, a pioneer in the development and production of benchtop and small-scale parallel bioreactor systems, and information technology. 
Through the combined strengths of the New Brunswick and DASGIP product portfolios and by utilizing the strong synergies in bioreactor technology and polymer manufacturing, Eppendorf has emerged as a global player and valuable resource to its customers in the bioprocess marketplace.

BBI SolutionsBBI Solutions
At BBI Solutions, our business is built on high quality products and outstanding customer partnerships.  We have over 25 years’ experience in the development and manufacture of protein reagents, both in native and recombinant form.

BBI Solutions offer cell culture proteins for the research, development and manufacture of advanced cell therapies and biologic drugs.  Our aim is to provide a secure supply of high quality, reliable and affordable proteins at the grade and scale you require.  Contact us to find out how we can support your move from research, through clinical stage and into the market.

DYNCPerfect for early development to ensure your process is scalable to commercial volumes. The PBS MAG-DRIVE is ideal for expansion of MSCs, T-Cells and pluripotent stem cells without the use of antifoams or anti-shear chemicals. Vertical-WheelTM technology results in homogenous mixing and reduced shear for uniform suspension of aggregates and micro-carriers during expansion as well as controlled differentiation.

The PBS MINI has working volumes as low as 100 mL for scalability to the PBS 500 and beyond. To find out more, please visit our website at www.pbsbiotech.com or email sales@pbsbiotech.com.

DYNC is representing the PBS range of Single Use Bioreactors in Europe. DYNC offers the full suite of support including application knowledge, maintenance and a complete inventory of the disposable vessels. Info@dync.eu or visit www.dync.eu.

Cook RegentecCook Regentec is focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient. Our team originated at Cook Medical, a medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools. Cook Regentec’s starting range of products includes cellular growth media, solutions for cryopreservation, and medical devices for the delivery of therapeutic agents. For more information, email us at information@cookregentec.com.


Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

Posters should be presented as A0 or US equivalent, size E (841mm x 1189mm or 34 x 44 inches respectively) in portrait orientation.

For further details and requirements please contact:

Ajay Nimbalkar
Email: ajay.nimbalkar@mnmconferences.com
Tel:+91 20 6708 0299

Posters Submission Form



Science MarketplaceScience Marketplace is a free platform which aims to facilitate all sorts of scientific exchanges including collaborations, services, jobs, studentships and conferences. In other words, to provide an online marketplace for scientists of all fields. Please post your expertise to establish new collaborations, showcase your company or university services, advertise jobs, conferences, etc.

European Society for BiomaterialsThe European Society for Biomaterials (ESB) was founded in March 1976, and became a member of the International Union of Societies for Biomaterials Sciences and Engineering (IUS-BSE) at its conception, in 1979. The ESB today has approximately 750 members from 33 different countries worldwide.

Tissue Engineering and Regenerative Medicine International SocietyTissue Engineering and Regenerative Medicine International Society -(TERMIS)
To accomplish its mission, the Society brings together the international community of persons engaged or interested in the field of tissue engineering and regenerative medicine and promotes education and research within the field of tissue engineering and regenerative medicine through regular meetings, publications and other forms of communication. The Society also serves as an international forum to promote the informed discussion of challenges and therapeutic benefits of the application of tissue engineering and regenerative medicine technologies.

The United Kingdom Society for Biomaterials (UKSB)The United Kingdom Society for Biomaterials (UKSB) was set up to serve the diverse, interdisciplinary biomaterials research community. This was in response to the findings of a joint working party of the Institute of Materials and the Institute of Physics & Engineering in Medicine. The UKSB is the democratic Society for the whole biomaterials community.



London Heathrow Marriott Hotel
Bath Road,
Heathrow Airport Hayes UB3 5AN
United Kingdom

Please note we have a group rate because of the volume of booking this event will generate.  We are not an agency and will not call you or try to sell you hotel deals or any ancillary services.  We get the venue to provide a secure online portal. You are free to make any arrangements you wish, but anyone calling or emailing claiming to represent us (especially a company called Exhibitors Housing Service) or to undercut our prices should be treated with a large degree of suspicion.

The London Heathrow Marriott Hotel has well-designed guest rooms which are complemented by intuitive service and comfortable amenities. The hotel’s location, a half mile from Heathrow Airport, allows guests to rest easy and enjoy stress-free travel connections with the airport’s handy Hoppa Bus shuttle service. Just a short drive from Twickenham Stadium, our hotel puts guests near motorways and the Heathrow Express so London attractions are only minutes away. Soundproof guest rooms include plush bedding, 24-hour room service and premium movie channels along with in-room laptop safes and large work areas. Five on-site restaurants, an indoor pool and fully-equipped Leisure Club provide added comfort and relaxation. Boasting 8,719 square feet of innovative event space, professional event managers and catering staff our hotel sets the stage for successful business and social events. Whether travelling on holiday or for business, our hotel is an ideal destination.


Our block of rooms at the London Heathrow Marriott has now expired.  You may still be able to book accommodation at the London Heathrow Marriott by visiting their website directly - http://www.marriott.co.uk/hotels/travel/lhrhr-london-heathrow-marriott-hotel/ Alternatively, you can see a list of nearby hotels by clicking here.

For further information please contact:
  • Steve Hambrook | Conference Director
  • steve.h@mnmconferences.com


London Heathrow Marriot Hotel

Heathrow Marriot Hotel - London

London Heathrow Hotel